Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip Dubovsky

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
Vaccine|March 2, 2010
Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growthJoseph T Bruder, Maureen E Stefaniak, Noelle B Patterson, et al.
The New England Journal of Medicine|February 3, 2023
Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373Katia Alves, Joyce S Plested, Shirley Galbiati, et al.
Plos Clinical Trials|July 28, 2006
RTS,S/AS02A malaria vaccine does not induce parasite CSP T cell epitope selection and reduces multiplicity of infectionSonia Enosse, Carlota Dobaño, Diana Quelhas, et al.
Infection and Immunity|May 24, 2005
Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trialGiane A Oliveira, Kristiane Wetzel, J Mauricio Calvo-Calle, et al.
Biorxiv : the Preprint Server for Biology|February 3, 2021
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccinesXiaoying Shen, Haili Tang, Charlene McDanal, et al.
Nature Communications|July 18, 2025
Single-dose avian influenza A(H5N1) Clade 2.3.4.4b hemagglutinin-Matrix-M<sup>®</sup> nanoparticle vaccine induces neutralizing responses in nonhuman primatesNita Patel, Asma Rehman, Jessica F Trost, et al.
Vaccine|October 22, 2008
A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malariaElissa Malkin, Jinhong Hu, Zhen Li, et al.
Vaccine|December 11, 2007
Safety of the RTS,S/AS02A malaria vaccine in Mozambican children during a Phase IIb trialJahit Sacarlal, John J Aponte, Pedro Aide, et al.
Vaccine|August 18, 2006
Viral vectors for malaria vaccine developmentShengqiang Li, Emily Locke, Joseph Bruder, et al.
Infection and Immunity|April 20, 2006
Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite proteinMichael Walther, Fiona M Thompson, Susanna Dunachie, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Vaccine|March 2, 2010
Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growthJoseph T Bruder, Maureen E Stefaniak, Noelle B Patterson, et al.
The New England Journal of Medicine|February 3, 2023
Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373Katia Alves, Joyce S Plested, Shirley Galbiati, et al.
Plos Clinical Trials|July 28, 2006
RTS,S/AS02A malaria vaccine does not induce parasite CSP T cell epitope selection and reduces multiplicity of infectionSonia Enosse, Carlota Dobaño, Diana Quelhas, et al.
Infection and Immunity|May 24, 2005
Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trialGiane A Oliveira, Kristiane Wetzel, J Mauricio Calvo-Calle, et al.
Biorxiv : the Preprint Server for Biology|February 3, 2021
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccinesXiaoying Shen, Haili Tang, Charlene McDanal, et al.
Nature Communications|July 18, 2025
Single-dose avian influenza A(H5N1) Clade 2.3.4.4b hemagglutinin-Matrix-M<sup>®</sup> nanoparticle vaccine induces neutralizing responses in nonhuman primatesNita Patel, Asma Rehman, Jessica F Trost, et al.
Vaccine|October 22, 2008
A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malariaElissa Malkin, Jinhong Hu, Zhen Li, et al.
Vaccine|December 11, 2007
Safety of the RTS,S/AS02A malaria vaccine in Mozambican children during a Phase IIb trialJahit Sacarlal, John J Aponte, Pedro Aide, et al.
Vaccine|August 18, 2006
Viral vectors for malaria vaccine developmentShengqiang Li, Emily Locke, Joseph Bruder, et al.
Infection and Immunity|April 20, 2006
Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite proteinMichael Walther, Fiona M Thompson, Susanna Dunachie, et al.
Pageof 6